VBI Poised To Take On GSK, Dynavax As Hep B Vaccination Market Takes Off

 
• By Joseph Haas

VBI Vaccines obtained FDA approval of its three-antigen hepatitis B vaccine PreHevbrio and will take on GSK’s Engerix-B and Dynavax’s Heplisav-B as CDC recommends universal HBV immunization.

Hepatitis B
VBI Vaccines hopes to take on entrenched competitors with a new HBV vaccine

More from New Products

More from Scrip